Testing for Irritation and Sensitization Kenneth R. St. John, PhD Chairman F04.16 Subcommittee on Biocompatibility Test Methods.

Slides:



Advertisements
Similar presentations
EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
Advertisements

EPAA Annual Conference 2007 Regulatory Acceptance and Implementation of 3Rs approaches Challenges for industry and regulators Dr. Hennicke Kamp BASF Aktiengesellschaft.
BIOLOGICAL PROPERTIES OF DENTAL MATERIALS (BIOCOMPATIBILITY)
The lymphatic system and immunity
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
HAZARDOUS MATERIALS CONTROL & MANAGEMENT. HAZMAT POINTS OF CONTACT l DOC/NOAA REGIONAL SAFETY MANAGER (This position is currently vacant, please contact.
09-Sep-2003 Predicting human risk with animal research: lessons learned from caffeine/ephedrine combinations Richard J. Briscoe, Ph.D. Safety Pharmacology.
No animal test please Animal Testing and Alternatives to Animal Testing Ekatrina from Uzbekistan Tseki from Mongolia.
Avoiding Pitfalls: Testing Considerations
Animal Models for Predicting Sensitization Potential Judith C. Stadler Haskell Laboratory, DuPont Company Newark, DE.
Dermal Toxicology Specialty Section What is Dermal Toxicology?The Dermal Toxicology Specialty Section Benefits of DTSS Membership The Officers of the DTSS.
Value of in vitro assays in your REACH dossier Frédérique van Acker 18 November 2014.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Preclinical Safety Assessment of Cosmetics & Toiletries Raman Govindarajan, MD, PhD. Regional Director Medical and Scientific Affairs Johnson and Johnson.
Section 1: Drugs Section 2: Drugs as Medicines Section 3: Drugs and the Brain.
Page Up to Reverse  Employee Health  Page Down to Advance  Employee Health 
DHHS / FDA / CDRH 1 Circulatory Support Devices Panel Tuesday, September 11, 2001 CoSeal® Surgical Sealant P
Responsibilities and Principles of Drug Administration
MB Research Laboratories New Photosensitization and Alternative Phototoxicity Methods George L. DeGeorge, Ph.D., DABT MB Research Laboratories.
Animal Models for Porcine Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure CTGTAC #47 May 14, 2009.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Biomedical Research Objective 2 Biomedical Research Methods.
Biomedical Research.
Chad B. Sandusky, Ph.D. Physicians Committee for Responsible Medicine, Washington DC, USA STRATEGIES TO REDUCE ANIMAL TESTING IN US EPA’S HIGH PRODUCTION.
Copyright © 2007 Pearson Education, Inc., publishing as Benjamin Cummings PowerPoint® Lectures Lectures by Greg Podgorski, Utah State University Protecting.
Animal Testing In our Cosmetic Products By: Victoria & Ramezy.
What is ISO 10993? How is it Different from USP Class VI?
Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Departments of Dermatology & Radiation Oncology University of Rochester Medical.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Friday, 5/2 4 Turn in “pre-lab” 4 Take out your LD50 worksheet Operating Engineers National Hazmat Program 1.
By: Carrie Bidwell (Clay High School) & Emily Zablocki (Adams High School)
UNDERSTANDING CHEMICAL ALLERGEN POTENCY THROUGH THE MOLECULAR EVENTS THAT TRIGGER IMMUNE CELL ACTIVATION Elena Kummer.
Your Body’s Defense. THE BODY’S CAPABILITY OF REMOVING OR KILLING FOREIGN SUBSTANCES, PATHOGENS AND CANCER CELLS Immunity.
ASTM F748 Selecting Biological Test Methods
Assessment of Drug Release and Permeation across Skin.
Case Study A New Motion-Sparing Spinal Disc Replacement Kenneth R. St. John, PhD Chairman F04.16 Subcommittee on Biocompatibility Test Methods.
Chapter 5 Wound Care. Copyright © 2007 Thomson Delmar Learning. ALL RIGHTS RESERVED.2 Pressure Ulcers Serious complication of immobility –Implement a.
Contact Dermatitis.
Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.
Laboratory safety rules Dalia Kamal Eldien Mohammed Practical NO (1)
Their methods of handling
ANTIMICROBIALS Chapter 10.
Analisa Stephens.  NSAID for pain and inflammation reduction ◦ Non-steroidal anti-inflammatory drugs  Localized Pain Patch ◦ Alternative to oral dosage.
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
Understanding Drugs and Medications What are drugs? Where do drugs come from? What are the different kinds of drugs and medicines? How do they enter the.
Copyright © 2010 Delmar, Cengage Learning. ALL RIGHTS RESERVED. Chapter 36 Calculation of Medication Dosage and Medication Administration.
CONSIDERATIONS FOR SURGICAL MEDICAL DEVICE TRIALS LCTU Liverpool Clinical Trials Unit Considerations for Medical Device Trials.
ASTM F748 Selecting Biological Test Methods
Drug Synthesis Noadswood Science, 2016.
Diagnosis of cell-mediated responses
with Audrey Turley, B.S., RM (NRCM), CBA (ASQ)
THE DOSE MAKES THE POISON
Toxicology in Cosmetics
Testing for Irritation and Sensitization
Diagnosis of cell-mediated responses
Safety Tests in Cosmetics
Safety Tests in Cosmetics
The lymphatic system and immunity
The Lymphatic System Pages
Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1  Osmond J. D'Cruz, Ph.D., Fatih M. Uckun,
ANTIMICROBIALS Chapter 10.
Topical Imiquimod Treatment Prevents UV-Light Induced Loss of Contact Hypersensitivity and Immune Tolerance  Thomas H. Thatcher, Irina Luzina, Rita Fishelevich,
IFN-τ inhibits IgE production in a murine model of allergy and in an IgE-producing human myeloma cell line  Mustafa G. Mujtaba, PhDa, Lorelie Villarete,
TGFβ1 Overexpression by Keratinocytes Alters Skin Dendritic Cell Homeostasis and Enhances Contact Hypersensitivity  Javed Mohammed, Andrew J. Gunderson,
INFLAMMATION ON FIRST CONTACT INFLAMATION ON REPEATED CONTACT
Objective 2 Biomedical Research Methods
IL-23 Antagonizes UVR-Induced Immunosuppression through Two Mechanisms: Reduction of UVR-Induced DNA Damage and Inhibition of UVR-Induced Regulatory T.
Hapten-Specific Tolerance Promoted by Calcitonin Gene-Related Peptide
Dendritic Cells Require T Cells for Functional Maturation In Vivo
Presentation transcript:

Testing for Irritation and Sensitization Kenneth R. St. John, PhD Chairman F04.16 Subcommittee on Biocompatibility Test Methods

Differences Irritation usually reflects the tissue response at first exposure to the material or chemical Sensitization usually refers to the response on repeat exposure, where the body has had the opportunity to develop an immune response In humans, it is not always possible to know whether a patient has previously been exposed, so knowing the potential for sensitization may prevent mild or major complications November 3, 2015Workshop on Medical Device Regulation2

Sensitizers in Medicine Incomplete list Nickel in metal alloys Latex Gloves Vial seals Needles Adhesive bandages Not necessarily addressing immune response to implants with skin tests, but the best options currently available November 3, 2015Workshop on Medical Device Regulation3

Tests Most experts and test documents suggest or require that materials or extracts be tested for irritation first at various doses and then the highest does for sensitization testing be the highest one that does not cause irritation Many or most tests are for skin sensitization or irritation Tests don’t really address implanted materials as well as maybe they could Tests for immune response with implantation may be useful November 3, 2015Workshop on Medical Device Regulation4

In Vivo Testing - Irritation November 3, 2015Workshop on Medical Device Regulation5 USP Irritation Test - Intracutaneous Injection Test Mucous Membrane Irritation Test – No ASTM Standard Edema and Erythema – Analogous to USP test but not stated to be an irritation test – toxicity is emphasized but scoring is identical to F719

Human Testing? November 3, 2015Workshop on Medical Device Regulation6

F719 - Irritation Clip hair from back Option to add depilatory (non-Irritating) Four sites, two intact and two abraded Place samples, two control, two test Cover with gauze and adhesive tape Wrap trunk with polyethylene film Remove after 24 hr Score at 1 hr, 24 hr, 48 hr after removal November 3, 2015Workshop on Medical Device Regulation7

F719 Calculate a primary irritation index, using formula in the specification, for each animal Average for all animals November 3, 2015Workshop on Medical Device Regulation8

Sensitization Testing “Sensitization of hypersensitivity reactions usually occur as a result of prolonged contact with a chemical substance that interacts with the body’s immune system. Because most such reactions to biomaterials have been of the dermal cell-mediated type, rather than the humoral or antigen-antibody type, the skin of laboratory animals is used in sensitivity testing” – Richard F. Wallin (see reference at the end of talk) November 3, 2015Workshop on Medical Device Regulation9

In Vivo Testing - Sensitization November 3, 2015Workshop on Medical Device Regulation10

In Vivo Testing - Sensitization “Biomaterials and other device materials are tested for the presence of sensitizing chemicals using guinea pigs. Guinea pig sensitization tests require six to eight weeks and thus take the longest time to complete of all the acute biocompatibility tests …” – Richard F. Wallin (see reference at the end of talk) November 3, 2015Workshop on Medical Device Regulation11

F720 - Sensitization Intradermal injection of an extract Three sites on each side of spine Adjuvant Sample without adjuvant Sample plus adjuvant One week later Sample in petroleum jelly or liquid on filter paper applied at each site Leave for 48 hours An additional week later Sample in petroleum jelly or liquid on filter paper applied at each site Leave for 24 hours Evaluate 1 Hr, 24 hr, 48 hr later Edema/Erythema scoring system (same as F719) November 3, 2015Workshop on Medical Device Regulation12

F Sensitization Intended to provide a different method of exposure that the Maximization test (F720), in which false positives were seen (both methods are internationally accepted) A table of dose applications over about a 28 day period Has a useful rationale and test comparison table in the appendix November 3, 2015Workshop on Medical Device Regulation13

F Sensitization Same scoring matrix as F719 and F720 More variations in the challenge types and intervals of repeated doses Some experts consider this to be potentially more meaningful in actual application All applications (with or without adjuvant) to the shaved skin but no skin injections November 3, 2015Workshop on Medical Device Regulation14

F Sensitization Lymph nodes in mice Extract applied to both ears daily for three days On day 6 Prepare and inject a radiolabeled tracer (tritiated thymidine) Five hours later, euthanize mice Collect the auricular lymph node from each ear Mash or otherwise cut up lymph nodes into very small pieces Centrifuge and wash 3 times (PBS) Replace supernatant with Tricloroacetic acid, resuspend and precipitate overnight Replace TCA supernatant with fresh Resuspend and count redioactivity November 3, 2015Workshop on Medical Device Regulation15

F2808 – Irritation Behind the Knee Controversial – Not Accepted by US FDA Possible that only the company that advocated for it actually uses it Mostly used for over-the-counter OB/Gyn products Places material behind the knee of human volunteers 6 hours per day for 5 days Normal activities cause mechanical irritation in addition to testing chemical irritation November 3, 2015Workshop on Medical Device Regulation16

Withdrawn Standards (2011) November 3, 2015Workshop on Medical Device Regulation17 Reflected an attempt to define in vitro tests for sensitization Withdrawal was controversial – may need to be reconsidered in the future

In Vitro Irritation and Sensitization International focus to reduce the number of animals used in product testing European Union Reference Laboratory for Alternatives to Animal Testing Develops and validates tests Has developed tests to assess irritation of cosmetics and chemicals A US testing laboratory is working on validating and offering in vitro tests to the medical device industry November 3, 2015Workshop on Medical Device Regulation18

In Vitro Irritation Testing Reconstructed human epidermis (RhE) Multi-Layered differentiated cell culture of human epidermis Polar and non-polar extracts MTT cytotoxicity test after exposure Assesses cell metabolic activity (viability) May become a non-animal option for irritation testing Accepted in Europe for chemicals and cosmetics EU Test Method B.46 and OECD Test Guideline (TG) 439 Would likely become a standardized method if validated November 3, 2015Workshop on Medical Device Regulation19 Source: Medical Product Manufacturing News Sept/Oct 2015

In Vitro Irritation Testing Positive control apparently has been found – is an irritant for both polar and non-polar solvents Validation will require proof of correlation with existing in vivo test results and/or clinical experience At least one US contract testing laboratory is pursuing its acceptance November 3, 2015Workshop on Medical Device Regulation20

In Vitro Sensitization Testing Three different tests are being developed One or a combination may end up being validated as non-animal tests Completion and validation is still in progress November 3, 2015Workshop on Medical Device Regulation21

Possible Reading Rollins, T., “Better Animal Testing Alternatives Are Coming To US,” Medical Product Manufacturing News, p.18-19, September 2015 Lister, L., “Biocompatibility Testing – Tips for Avoiding Pitfalls – Part 2,” Wallin, R. F., “A Practical Guide to ISO : Sensitization,” Wallin, R. F., “A Practical Guide to ISO : Irritation,” November 3, 2015Workshop on Medical Device Regulation22